Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.35 |
| ▸ | IL1B | P01584 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | PDE6D | O43924 | 3/20 | 0.34 |
| ▸ | PDE6A | P16499 | 3/20 | 0.34 |
| ▸ | PDE6G | P18545 | 3/20 | 0.34 |
| ▸ | PDE6B | P35913 | 3/20 | 0.34 |
| ▸ | PDE6C | P51160 | 3/20 | 0.34 |
| ▸ | PDE6H | Q13956 | 3/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23830284 | 0.94 | PDE6D (0.36) | P2RX7IL1BCHRM1PDE6DPDE6A | |
| SCHEMBL23830333 | 0.91 | P2RX7 (0.35) | P2RX7IL1BCHRM1 | |
| SCHEMBL23830271 | 0.87 | PDE6D (0.37) | P2RX7IL1BCHRM1PDE6DPDE6A | |
| SCHEMBL23830422 | 0.85 | P2RX7 (0.37) | P2RX7IL1BCHRM1PDE6DPDE6A | |
| SCHEMBL23830400 | 0.83 | RORC (0.35) | GABRA5 | |
| SCHEMBL23830350 | 0.83 | P2RX7 (0.37) | P2RX7IL1BCHRM1PDE6DPDE6A | |
| SCHEMBL23830300 | 0.82 | CHRM1 (0.36) | P2RX7IL1BCHRM1PDE6DPDE6A | |
| SCHEMBL23830311 | 0.81 | SCN9A (0.39) | P2RX7IL1BCHRM1PDE6DPDE6A | |
| SCHEMBL23830304 | 0.79 | PDE6D (0.53) | P2RX7IL1BCHRM1PDE6DPDE6A | |
| SCHEMBL23830334 | 0.79 | PDE6D (0.38) | P2RX7IL1BPDE6DPDE6APDE6G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | CADILA HEALTHCARE LIMITED (IN) | 2021-09-23 | — | — | US | claimed |
| CN-112543757-A | Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus | 卡迪拉保健有限公司 | 2021-03-23 | — | — | CN | claimed |
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | CADILA HEALTHCARE LIMITED (IN) | 2021-09-23 | — | — | US | disclosed |
| CN-112543757-A | Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus | 卡迪拉保健有限公司 | 2021-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | DPEP1, SAT1, PEPD | P2RX7 3325/4885IL1B 1733/4885CHRM1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.